Mark-David Levin

32PUBLICATIONS
165CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRehabilitation engineeringInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Mar 27, 2026
FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Bastien Jamet, Shamimeh Ahrari, Sonja Zweegman

|Feb 25, 2026
Cost-Effectiveness of Venetoclax-Based Treatment in Treatment-Naïve Fit Patients With CLL Without TP53 Aberrations.

Lars Holger Ehlers, Mark-David Levin, Marjolein van der Klift

|Sep 24, 2025
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.

Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Aug 22, 2025
Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Febe Smits, Kaz Groen, Mark-David Levin

Pageof 6

Frequent Collaborators

10 joint publications

Arnon P Kater

8 joint publications

Peter E Westerweel

8 joint publications

Carsten Utoft Niemann

7 joint publications

Anton W Langerak